Galectin Therapeutics
GALT
76 hedge funds and large institutions have $35.4M invested in Galectin Therapeutics in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 15 closing their positions.
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
17% more funds holding
Funds holding: 65 → 76 (+11)
0.78% less ownership
Funds ownership: 16.03% → 15.25% (-0.78%)
5% less capital invested
Capital invested by funds: $37.3M → $35.4M (-$1.94M)
39% less call options, than puts
Call options by funds: $894K | Put options by funds: $1.46M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.28M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.81M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$820K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$542K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$496K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.52M |
| 2 |
Goldman Sachs
New York
|
-$891K |
| 3 |
LCM
Laurion Capital Management
New York
|
-$877K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$794K |
| 5 |
JP Morgan Chase
New York
|
-$773K |
GALT Hedge Fund Activity: Q2 2019 in Review
76 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2019, worth a combined $35.4M — down 5.2% from $37.3M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new GALT positions and 15 closed out — a net gain of 12 holders — while 23 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $6.28M. The largest seller was Millennium Management, cutting an estimated $1.52M.
- 76 institutional investors held Galectin Therapeutics (GALT) as of Q2 2019, up from 65 in Q1 2019.
- Funds reported $35.4M of Galectin Therapeutics stock for Q2 2019, down 5.2% quarter-over-quarter.
- 27 funds opened new Galectin Therapeutics positions in Q2 2019 and 15 closed out, a net change of +12 holders.
- The largest Galectin Therapeutics buyer in Q2 2019 was BlackRock, an estimated $6.28M added.
- The largest Galectin Therapeutics seller in Q2 2019 was Millennium Management, an estimated $1.52M sold.
Based on aggregated 13F filings for Q2 2019.